Adamsen Sven, Bendix Jørgen, Kallehave Finn, Moesgaard Flemming, Nilsson Tove, Wille-Jørgensen Peer
Department of Gastrointestinal Surgery D-113, Copenhagen University Hospital Herlev, Herlev, Denmark.
Scand J Gastroenterol. 2007 Mar;42(3):318-23. doi: 10.1080/00365520600880989.
To investigate treatment practice in non-variceal upper gastrointestinal bleeding (NVUGIB) caused by gastroduodenal ulcer and how it adheres to the best evidence as documented in randomized studies and meta-analyses.
The literature was surveyed to identify appropriate practices, and a structured multiple choice questionnaire developed and mailed to all departments in Denmark treating UGIB.
All 42 departments responded. All had therapeutic gastroscopes and equipment necessary for endoscopic haemostasis; 90% of departments had written guidelines. Adjuvant pharmacologic treatment included tranexamic acid in 38%. Proton-pump inhibitors (PPIs) were used by all departments, with 29% starting prior to endoscopic treatment. Eight departments (19%) used continuous PPI infusion, three of them starting with a bolus dose. In 50% of departments an anaesthesiologist was always present regardless of whether endotracheal intubation (routinely used by 10%) was used or not. Ten percent did not treat Forrest IIa and IIb ulcers, while IIc ulcers were treated by 36%. In 10% of departments clots were never removed, while in 2/3 attempts were made to remove resistant clots by mechanic means. Seven departments (17%) used monotherapy with epinephrine, while 59% always used dual therapy; 19% injected less than 10 ml. In rebleeding, 92% attempted endoscopic treatment before surgery, and used epinephrine in 79% of cases, while the remainder used epinephrine or polidocanol at the discretion of the endoscopist. Two out of three departments used high-dependency or intensive-care units for surveillance. Seventeen percent applied scheduled second-look gastroscopy.
Practice is variable, even in areas with established evidence based on randomized controlled studies, such as dosage and way of administration and duration of PPI treatment, injection treatment used as monotherapy and the volume used, including ulcers with clots for treatment, and the use of scheduled second-look endoscopy. Since the rebleeding rate has remained unchanged for decades, and rebleeding implies increased surgery and mortality rates, appropriate practices must be promoted in order to improve results. Development and implementation of national guidelines may facilitate the process.
探讨胃十二指肠溃疡所致非静脉曲张性上消化道出血(NVUGIB)的治疗实践,以及其与随机研究和荟萃分析中记录的最佳证据的符合程度。
对文献进行检索以确定合适的实践方法,并编制了一份结构化的多项选择题问卷,邮寄给丹麦所有治疗UGIB的科室。
所有42个科室均作出回应。所有科室都配备了治疗性胃镜及内镜止血所需设备;90%的科室有书面指南。辅助药物治疗中,38%使用氨甲环酸。所有科室均使用质子泵抑制剂(PPI),29%在内镜治疗前开始使用。8个科室(19%)采用PPI持续输注,其中3个科室先给予负荷剂量。50%的科室无论是否使用气管插管(10%常规使用),麻醉医生始终在场。10%的科室不治疗福里斯特IIa和IIb级溃疡,而36%的科室治疗IIc级溃疡。10%的科室从不清除血凝块,而2/3的科室尝试通过机械方法清除顽固血凝块。7个科室(17%)使用肾上腺素单一疗法,59%始终使用联合疗法;19%的注射量少于10毫升。对于再出血,92%在手术前尝试内镜治疗,79%的病例使用肾上腺素,其余则由内镜医生酌情使用肾上腺素或聚多卡醇。三分之二的科室使用高依赖或重症监护病房进行监测。17%的科室进行计划性二次胃镜检查。
即使在基于随机对照研究已有证据的领域,实践也存在差异,如PPI治疗的剂量、给药方式和持续时间、作为单一疗法使用的注射治疗及其使用量,包括对有血凝块溃疡的治疗,以及计划性二次内镜检查的使用。由于几十年来再出血率一直未变,而再出血意味着手术和死亡率增加,因此必须推广合适的实践方法以改善治疗效果。制定和实施国家指南可能会推动这一进程。